ArticlePhysiological research2026
Mirogabalin Eliminated Pain and Reduced Inflammation in Visceral Pain.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirogabalin is a newly developed gabapentinoid drug. Several in vivo and clinical studies have demonstrated the potent analgesic effects of mirogabalin in neuropathic pain. This study aims to investigate the impact of mirogabalin on visceral pain and inflammation. Adult male Balb/c mice (20-25 g) were used in the study (n=7). Mirogabalin was administered intraperitoneally at 10, 20, and 40 mg/kg doses. Inflammatory visceral pain was induced by intraperitoneal administration of acetic acid. The number of writhing was observed after acetic acid administration, and the effective dose of mirogabalin was determined. In the second phase of the study, the effects of mirogabalin on locomotor activity and leukocyte infiltration into peritoneal tissue were examined. IL-6, GSH levels, and SOD activity were investigated biochemically. Statistical analyses were performed in the GraphPad Prism (v8.0.1) program. Mirogabalin was significantly antinociceptive at all three doses (p<0.001). Histopathologic examination showed that the effective dose of mirogabalin decreased leukocyte infiltration into the peritoneum. Mirogabalin did not affect total distance moved and mean speed in the open field test. There was no significant difference between the groups in terms of IL-6, GSH levels, and SOD activity. Our results demonstrated a significant antinociceptive effect of mirogabalin against visceral pain. In addition, anti-inflammatory effects were revealed by decreasing leukocyte infiltration. However, the fact that mirogabalin did not alter antioxidant systems and IL-6 levels suggests that other mechanisms are responsible for its anti-inflammatory effects. Key words Mirogabalin " Pain " Inflammation " Visceral " GABA.
Indexed as
Identifiers
41823095PMC13127987What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.